Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery

Jun 2013| PHM066B| BCC Publishing

Report Highlights

The global market for ubiquitin proteasome research and development was estimated at nearly $2.9 billion in 2013. The market should total more than $5.5 billion by 2018, and have a five-year compound annual growth rate (CAGR) of 14.2% from 2013 to 2018.

Report Includes

  • An overview of the state of research tools, diagnostics, and drug discovery in the global ubiquitin proteasome (UPS) research field.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Discussion of existing products in the market.
  • Identification of two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets.
  • This study notes the trends that are going to affect further drug development in this area.

SCOPE AND FORMAT

This report is essentially a business tool that can help market players evaluate properly new commercial opportunities in the ubiquitin proteasome space especially in the drug discovery, diagnostics and research tools submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment and forecasts market growth, future trends and product development in every major segment of this market.

Frequently Asked Questions (FAQs)

Analyst Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery150Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY2Free
Chapter- 3: SCIENTIFIC BACKGROUND AND SIGNIFICANCE OF UBIQUITIN PROTEASOME RESEARCH8Free
Chapter- 4: UBIQUITIN PROTEASOME SYSTEM AND DRUG DISCOVERY78Free
Chapter- 5: THE UBIQUITIN PROTEASOME SYSTEM AS A DIAGNOSTIC TOOL 15Free
Chapter- 6: REAGENTS AND ASSAY DEVELOPMENT FOR UPS RESEARCH AND DRUG DISCOVERY 13Free
Chapter- 7: MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT AND SIGNIFICANCE OF PATENTS 9Free
Chapter- 8: MARKET SUMMARY 4Free
Chapter- 9: SELECT COMPANIES AND PROFILES9Free
Chapter- 10: LIST OF COMPANIES MENTIONED IN REPORT9Free
Published - Jul-2010| Analyst - Marianna Tcherpakov| Code - PHM066A

Report Highlights

  • There is only one approved UPS product on the market, Velcade, a proteasome inhibitor, with total sales of more than $1.4 billion in 2009. This drug is expected to be worth $3 billion in 2015, a compound annual growth rate (CAGR) of 13.5% over the study period.
  • In the U.S., Velcade was worth $468 million in 2009 and is expected to reach $1 billion in 2015, a compound annual growth rate (CAGR) of 13.5%. 
  • Worldwide, Velcade was valued at $933 million in 2009 and is expected to reach $2 billion by 2015, a compound annual growth rate (CAGR) of 13.6%.
Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
RELATED REPORTS